Innovative Cancer Medicines in China
Overview
China has become one of the world’s fastest-moving markets for innovative oncology drugs: domestically developed targeted therapies, immunotherapies and antibody-drug conjugates frequently achieve Chinese approval before or alongside international availability, often at substantially lower prices.
This program provides international patients structured access to these novel agents — through hospital pharmacy channels, expanded-access pathways and registered clinical trials at major cancer centers.
Symptoms & Signs
Indications are defined by the underlying cancer and its molecular profile rather than symptoms alone
Disease progressing despite standard first- and second-line therapy
Actionable mutations or biomarkers identified by genomic testing for which novel agents exist
Intolerance of conventional therapy requiring alternative agents
Tumors with rare targets, such as NTRK fusions or RET alterations
No approved standard therapy remaining — the classic clinical-trial situation
Diagnosis
Comprehensive genomic profiling (tissue and liquid biopsy NGS) identifying actionable targets
Pathology review confirming diagnosis and biomarker status
PD-L1, MSI and tumor-mutation-burden testing for immunotherapy suitability
Re-staging imaging establishing the disease baseline
Organ-function assessment confirming eligibility for novel agents
Review of prior therapies documenting standard-care exhaustion
Treatment Options
Domestically developed EGFR, ALK and ROS1 inhibitors for lung cancer, several China-first approvals
Anti-PD-1/PD-L1 immunotherapies across a dozen approved indications
Antibody-drug conjugates for breast, gastric, urothelial and other cancers
CAR-T and other cell therapies for hematologic malignancies
Registered clinical trials offering access to pipeline agents
Named-patient and expanded-access programs where regulations permit
Advanced Technologies & Novel Drug
Central pharmacy channels for domestically approved novel oncology drugs
Next-generation sequencing infrastructure supporting precision prescribing
Phase I and dose-expansion trial units at major cancer centers
Bispecific antibody and ADC platforms in active development
Real-world data programs tracking novel-agent outcomes
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Peking University People's Hospital — Beijing
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin
- Li Jun Ling — Medical Oncology
- Wang Xing Yuan — Medical Oncology
- Zhang Xiao Shi — Medical Oncology
- Lin Tong Yu — Medical Oncology